key: cord-1016017-wq6bd5rn authors: Fang, Yuan; Yang, Chao; Yu, Zhiqiang; Li, Xiaochuan; Mu, Qingchun; Liao, Guochao; Yu, Bin title: Natural products as LSD1 inhibitors for cancer therapy date: 2020-06-20 journal: Acta Pharm Sin B DOI: 10.1016/j.apsb.2020.06.007 sha: 467c5088db15e117590f0002a06f3ad2a95a8dae doc_id: 1016017 cord_uid: wq6bd5rn Natural products generally fall into the biologically relevant chemical space and always possess novel biological activities, thus making them a rich source of lead compounds for new drug discovery. With the recent technological advances, natural product-based drug discovery is now reaching a new era. Natural products have also shown promise in epigenetic drug discovery, some of them have advanced into clinical trials or are presently being used in clinic. The histone lysine specific demethylase 1 (LSD1), an important class of histone demethylases, has fundamental roles in the development of various pathological conditions. Targeting LSD1 has been recognized as a promising therapeutic option for cancer treatment. Notably, some natural products with different chemotypes including protoberberine alkaloids, flavones, polyphenols, and cyclic peptides have shown effectiveness against LSD1. These natural products provide novel scaffolds for developing new LSD1 inhibitors. In this review, we mainly discuss the identification of natural LSD1 inhibitors, analysis of the co-crystal structures of LSD1/natural product complex, antitumor activity and their modes of action. We also briefly discuss the challenges faced in this field. We believe this review will provide a landscape of natural LSD1 inhibitors. Natural products have long been recognized as a rich source of leads for new drug discovery. Relative to synthetic compounds, natural products possess diverse scaffolds and retain a high degree of stereochemistry 1 . Natural products are inherently within regions of biologically relevant chemical space and more importantly cover larger space than synthetic small-molecule libraries 2 . As reported, 48 .6% (85) of the 175 small-molecule antitumor agents approved from around the 1940s to 2012 are either natural products or analogs derived natural products ( Fig. 1) 3, 4 . William C. Campbell, Satoshi Omura, and Youyou Tu were awarded the 2015 Nobel Prize in Physiology or Medicine for their achievements on the discovery of naturally occurring avermectins and artemisinin, respectively, for treating devastating parasite diseases 5 . With the recent technological advances, particularly the functional assays and phenotypic screening, many natural products are currently being used as valuable starting points in drug discovery campaigns for novel therapeutics beyond their traditional antimicrobial and anticancer indications [6] [7] [8] . With the epidemic of coronavirus disease , numerous efforts have been devoted to identifying effective drugs/vaccines for combating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Of note, some natural products have shown effectiveness for treating 2019 novel coronavirus pneumonia 9 . It is evident that the natural product-based drug discovery is now reaching a new golden age. In last decades, natural products have been used as starting points for epigenetic probe or drug discovery 10 Mechanistically, the disulfide bridge of this bicyclic compound is reduced by glutathione to give free thiol groups, which then interact with Zn ions within the active site of HDAC enzymes, thus inhibiting the deacetylase activity 12 . Of the epigenetic targets, the lysine-specific histone demethylase 1A (LSD1, also known as KDM1A) specifically removes methyl marks of histone H3 lysine 4 (H3K4) in flavin adenine dinucleotide (FAD)-dependent manner 13 . LSD1 has fundamental and diverse roles in physiological processes 14 and under pathological conditions, such as cancers 15, 16 , infections 17, 18 , immune modulation [19] [20] [21] , etc. LSD1 dysregulation has been found in a wide range of cancers and is closely associated with malignant transformation, the epithelial-mesenchymal transition (EMT), stem cell biology, and cell proliferation and differentiation 22 . LSD1 inhibition by small molecules or genetic knockdown has shown effectiveness in blocking cell growth and migration 23,24 , inducing differentiation 25, 26 , etc. These findings strongly suggest that targeting LSD1 is a promising option for cancer therapy [27] [28] [29] [30] . To date, a large number of highly potent and selective LSD1 inhibitors have been reported in last decades [31] [32] [33] [34] [35] , of which tranylcypromine (TCP), ORY-1001, ORY-2001, GSK-2879552, INCB059872, IMG-7289, and CC-90011 are currently undergoing clinical evaluation at different phases for the treatment of cancers 36 . Of particular interest is that some natural products could effectively inhibit LSD1 even at nanomolar levels ( Fig. 2) . Although the significant progress on natural LSD1 inhibitors has been observed, no comprehensive reviews have been published to date. Therefore, it would be necessary and of great interest to give an updated summary of natural product-based LSD1 inhibitors. In this review, an emphasis will be placed on the identification of natural LSD1 inhibitors, analysis of the co-crystal structures of LSD1/natural product complexes, antitumor activity and their modes of action. We will also briefly discuss the opportunities and challenges faced in this field. We believe this review will provide a landscape of natural LSD1 inhibitors and be interesting to the readers in this field. Due to the structural diversity and complexity, natural products generally fall into the biologically relevant chemical space and cover wider space that is not occupied by synthetic compounds, thus always possessing unexpected biological activities. These attributes make natural products a rich source of lead compounds for new drug discovery. To date, some natural products with different chemotypes including protoberberine, flavone, diterpenoid, curcumin, xanthone, stilbene, resveratrol, secoiridoid, indole, phenol, and cyclic peptide, have been reported to be capable of inhibiting LSD1 in vitro and/or in vivo. This section is organized according to the scaffold types of natural LSD1 inhibitors. The H3 N-terminal residues bind to an open cleft in LSD1-CoRESt (RE1-silencing transcription factor co-repressor) and form interactions with surrounding negatively charged amino acid residues. Based on the structural features, Speranzini et al. 37 screened their in-house focused library containing compounds with positively charged groups by thermal shift assay using ThermoFAD and in vitro anti-LSD1 enzymatic assay. Interestingly, they found that natural cyclic peptides polymyxins B and E (Table 1 ) could inhibit LSD1 in the thermal shift assay. In structure, polymyxins B and E feature five positively charged amine units (highlighted in blue in Table 1 ) and possess a linear head group, thus possibly mimicking histone H3 peptide substrates for binding to LSD1. In the thermal shift assay, both compounds increased the melting temperature (ΔT m =6 °C) of LSD1-CoREST. The enzymatic and fluorescence polarization assays showed that polymyxins B and E competitively bound to LSD1-CoREST with histone H3 peptide and showed favorable affinity with K i and K d values of (157 to 193) and (463-594) nmol/L, respectively (Table 1 ). In cultured leukemia MV4-11 cells, polymyxin E (1 μmol/L), because of the poor permeability, had no remarkable effects on either H3K4/H3K9 (histone H3 lysine 9) methylation or cell growth. Co-crystal structure (PDB code: 5L3F) of LSD1-CoREST in complex with polymyxin B revealed that this positively charged cyclic peptide bound to LSD1 at the H3 tail-binding region, far away from the flavin (>5 Å) and formed electrostatic interactions with surrounding negatively charged residues (highlighted in red in Fig. 3B ). Besides, because of the circular nature and multiple orientations, polymyxin B may adapt other "rotated" orientations with lower occupancies, the evidence supporting this notion is that polymyxin B showed decreased affinity (K d = 4.7±0.7 μmol/L) by a factor of 10 toward mutant LSD1, in which Glu379 was substituted with Lys. This substitution from Glu to Lys reversed the charge of the key residue interacting with polymyxin B. This identified highly charged protein surface area is larger than that previously exploited 38 , and thus particularly attractive for designing new LSD1 inhibitors suppressing the demethylase activity and impairing binding to LSD1-CoREST. Although the serious side effects observed in anti-infection treatments, these findings highlight that the well-known antibiotics polymyxins B and E could be potentially repurposed for regulating bacterial infections and epigenetic processes in the context of leukemia. Through screening our in-house compound library containing natural products, we found that the tetracyclic protoberberine alkaloids potently inhibited LSD1 (Table 2) 39 . Of note, epiberberine showed the strongest inhibitory activity against LSD1 (IC 50 = 0.14 μmol/L), while other protoberberine alkaloids showed decreased inhibitory activity, suggesting the crucial roles of substituents on the activity. We also noted that the tetracyclic canadine and tetrahydropalmatine were inactive against LSD1 with the IC 50 values of over 100 μmol/L. This strongly indicate that the isoquinoline ring is extremely important for the anti-LSD1 activity. The structure-activity relationship studies (SARs) provide us the essential structural features of protoberberine alkaloids for LSD1 inhibition, we believe the protoberberine alkaloids could be used as starting templates for designing more potent and selective LSD1 inhibitors. Further structural modifications based on the tetracyclic scaffold is currently undergoing in our lab. In contrast to LSD1, epiberberine was less potent against monoamine oxidase A/B (MAO-A/B), showing selective inhibition toward LSD1. At 1.0 μmol/L, epiberberine inhibited LSD1 with an inhibitory rate of 89.41%, but had <30% of inhibitory rates against MAO-A/B. Epiberberine reversibly inhibited LSD1 and was non-competitive with LSD1 substrate H3K4me2. In the surface plasmon resonance (SPR) assay, epiberberine bound to LSD1 with a fast association (K a = 3.55×10 3 L/mol·s) but with a slow dissociation (K d = 4.32×10 -2 s -1 ). In acute myeloid leukemia (AML) cell lines THP-1 and HL-60, epiberberine moderately inhibited cell growth after 8 days' treatment (IC 50 = 12.80 and 23.82 μmol/L, respectively). In THP-1 cells, epiberberine had no effect on LSD1 expression, but induced accumulation of LSD1 substrates The flavones are a large family of natural products that possess diverse biological activities 42, 43 . In recent years, some flavone-based natural compounds have proven to be effective against LSD1 (Fig. 4) [44] [45] [46] . In structure, the flavones feature the backbone of 2-phenylchromen-4-one with additional phenolic hydroxy groups and/or sugar moiety. The in vitro inhibitory activity of these flavones against LSD1 is depicted in In 2016, our group reported that baicalin could inhibit LSD1 with an IC 50 of 3.01 μmol/L (similar to that later reported by Han et al. 45 ) and the HillSlope value of 0.67 44 . Baicalin is the first reported flavone-based natural LSD1 inhibitor. In MGC-803 cells overexpressing LSD1, baicalin dose-dependently induced accumulation of H3K4me2 and CD86 messenger RNA (mRNA) levels, but had no effect on LSD1 expression, Specifically, relative to the control group or isoquercitrin-treated group, co-treatment with isoquercitrin and siRNA caused lower mitochondrial transmembrane potential (ΔΨ m ) and higher BAX/BCL-2 protein ratio as well as induced expression of cleaved caspase-3, caspase-7, caspase-9, and PARP. Xanthones are an important class of polyphenolic compounds with diverse pharmacological activities, thus making them promising scaffolds for new drug discovery [47] [48] [49] [50] . Of which α-mangostin (α-MG, Fig. 6 ), the main constituent of the mangosteen fruit, has been proved to possess diverse pharmacological properties 51,52 . Han et al. 53 Stilbenes are an important class of biologically active scaffolds structurally featuring a trans-1,2-diphenylethylene nucleus (highlighted in blue in Fig. 7) . The stilbene scaffolds are prevalent in natural products including resveratrol (Fig. 7) and biologically active compounds, thus being recognized as privileged scaffolds in drug discovery [54] [55] [56] [57] . Resveratrol has shown diverse biological activities and is therapeutically potential in preventing or slowing the progression of various pathological conditions, including cancers, cardiovascular diseases, type 2 diabetes, etc. 58 . Additionally, it has been reported that resveratrol could activate the nicotinamide adenine dinucleotide (NAD + )-dependent histone deacetylase sirtuin 1 (SIRT1) 59 , thus potentially achieving epigenetic regulation. In 2013, Abdulla et al. 60 reported that resveratrol dose-dependently inhibited the enzymatic activity of LSD1 (IC 50 = 15 μmol/L) and also inhibited the demethylation process of H3K4me2. The inhibitory activity of resveratrol against LSD1 was independent on its antioxidant properties and was specific, not through SIRT1 activation. For myogenic differentiation of C2C12 fibroblasts, LSD1 is required 61 . The authors found that in C2C12 cells, resveratrol effectively inhibited myocyte formation and myosin heavy chain (MHC) expression. Finally, they speculated that resveratrol bound to LSD1 to inhibit its demethylase activity. The data may suggest that resveratrol would be a good starting point for designing new LSD1 inhibitors. The diarylheptanoids, a class of natural products mainly distributed in the roots, bark and rhizomes of Alpinia, Curcuma, Zingiber and Alnus species, possess the aryl-C7-aryl skeleton and various substituents 64 . Such compounds have shown diverse biological activities such as anticancer, antimicrobial, and antioxidant activity, thus becoming a promising class of bioactive natural products 65 . Of particular interest is curcumin (Fig. 8) , which is a constituent of turmeric derived from the roots of plant Curcuma longa 66 . As a natural polyphenol, curcumin has shown numerous biological activities including antioxidant, anti-inflammatory, and anticancer properties and has been one of the focuses for new drug development 67, 68 . Accumulating data have supported the therapeutic potential of curcumin as an epigenetic modulator and warrant further preclinical and clinical studies for exploring its anticancer efficacy 69, 70 . In 2013, Abdulla et al. 60 Melatonin (Fig. 9) , a natural hormone produced primarily by the pineal gland in the brain, is functionally diverse, including anticancer, antioxidant, anti-inflammatory and immune-regulating activity 74 . Melatonin may have the therapeutic potential against a variety of cancer types 75, 76 , particularly the gastrointestinal cancer 77 . Interestingly, melatonin could induce histone H3 hyperacetylation 78, 79 and apoptosis of colorectal cancer cells through histone deacetylase 4 (HDAC4) nuclear import 80 . In 2017, Yang et al. 81 revealed that melatonin showed therapeutic potential in patient-derived tumor xenograft (PDTX) models bearing oral cancer cells via suppressing LSD1. After treatment for 42 days, melatonin inhibited tumor growth and weight significantly without observed toxicities. In contrast to the control group, LSD1 expression was significantly lower in the melatonin-treated group. Melatonin induced cell cycle arrest of SAS cells at G0/G1 phase and decreased expression of LSD1 in both SAS and SCC25 cells. In SCC25 cells, melatonin significantly led to elevated levels of P21 and decrease levels of cyclin D1. The data may suggest that melatonin may has therapeutic potential in LSD1-overexpressed oral cancer. However, questions remain exit for the anti-oral cancer effects of melatonin, for example, the authors did not address whether melatonin bound to LSD1 directly or indirectly, the cellular target engagement was not examined as well. More work should be done before carrying out melatonin-based modifications for more potent and selective LSD1 inhibitors. Geranylgeranoic acid (GGA, Fig. 10 Natural products feature diverse and novel molecular scaffolds, and thus are a rich source for identifying new bioactive compounds. Of note, with the recent development of the functional assays and phenotypic screening protocols, more and more natural products have demonstrated novel therapeutics beyond their traditional antimicrobial and anticancer indications. Youyou Tu, Satoshi Omura, and William C. Campbell were awarded the 2015's Nobel Prize in Physiology or Medicine for discovering avermectins and artemisinin for treating parasite diseases. Undoubtedly, natural product-based drug discovery is now reaching a new golden age. In the field of epigenetics, natural products have also shown promise in epigenetic drug discovery. To date, numerous natural products have been reported to be able to modulate epigenetic processes, some of them have advanced into clinical trials or are presently being used in clinic. LSD1 has fundamental roles in the development of various pathological conditions, including cancers. Pharmaceutical inhibition of LSD1 has been a promising therapeutic option for cancer treatment 86 . Some TCP-based LSD1 inhibitors are currently being evaluated for cancer therapy. Notably, some natural products of different types have also shown effectiveness in inhibiting LSD1. Generally, these natural products can be mainly divided into four categories, including cyclic peptides, protoberberine alkaloids, polyphenols, and unsaturated carbonyl compounds (e.g., GGA). These natural products indeed provide novel scaffolds for developing new reversible LSD1 inhibitors. However, most of them show poor to moderate inhibitory activity against LSD1, much efforts should be devoted to identifying new LSD1 inhibitors with novel scaffolds from nature. The "2+1" model previously proposed by us 33 has been successfully used to design new LSD1 inhibitors in our lab [87] [88] [89] [90] [91] and would also be useful to guide the selection of potential hit compounds from natural product library for further screening. We have to admit that biological characterization of natural LSD1 inhibitors is at very early stage, most of them are not fully characterized in vitro and in vivo. Before further structural modifications and/or in-depth mechanistic studies, any hit compound inhibiting LSD1 should be carefully cross-validated to make sure that it is a genuine LSD1 inhibitor. Particular attention should be paid to natural polyphenols, which always consume H 2 O 2 (produced in the screening assay), and then give a false positive reading. Besides, some compounds with aromatic character appear to be LSD1 inhibitors, but are actually horseradish peroxidase (HRP, a component used in the screening assay) inhibitors. This kind of compounds also give a false positive reading and should be excluded. Collectively, herein we provide an updated overview of natural LSD1 inhibitors reported to date and our own perspectives on future development of novel LSD1 inhibitors based on natural products. The scaffolds derived from natural products could be used for designing new LSD1 inhibitors. In this review, the identification of natural LSD1 inhibitors, analysis of the co-crystal structures of LSD1/natural product complex, antitumor activity, their modes of action, and the challenges faced in this field were mainly discussed. This review will provide a landscape of natural LSD1 inhibitors. The use of isolated natural products as scaffolds for the generation of chemically diverse screening libraries for drug discovery The re-emergence of natural products for drug discovery in the genomics era Natural products as sources of new drugs from 1981 to 2014 Structural simplification: an efficient strategy in lead optimization A new golden age of natural oroducts drug discovery Underexplored opportunities for natural products in drug discovery Natural products in drug discovery Drug discovery and natural products: dnd of an era or an endless frontier? Traditional Chinese medicine: an effective treatment for 2019 novel coronavirus pneumonia (NCP) Perspectives on natural product epigenetic modulators in chemical biology and medicine Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma New techniques and strategies in drug discovery Histone demethylation mediated by the nuclear amine sxidase homolog LSD1 LSD1, a double-edged sword, confers dynamic chromatin regulation but commonly promotes aberrant cell growth The histone LSD1 demethylase in stemness and cancer transcription programs Expanding the role of the histone lysine-specific demethylase LSD1 in cancer Inhibition of LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic suppression of viral genomes Trends of LSD1 inhibitors in viral infections LSD1 Ablation stimulates anti-tumor immunity and enables checkpoint blockade Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis Lysine-Specific Demethylase 1 (LSD1) Inhibitors as potential treatment for different types of cancers LSD1 inhibition suppresses the growth of clear cell renal cell carcinoma via upregulating P21 signaling Pharmacological inhibition of LSD1 activity blocks REST-dependent medulloblastoma cell migration Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia Lsd1 inhibition induces differentiation and decreases leukemic stem cell frequency in Hoxa9/Meis1-driven AML Lysine-Specific Demethylase 1A as a promising target in acute myeloid leukemia Pharmacological inhibition of LSD1 for cancer treatment Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations Targeting histone lysine demethylase LSD1/KDM1A as a new avenue for cancer therapy Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date A systematic review of histone lysine-specific demethylase 1 and its inhibitors Advances toward LSD1 inhibitors for cancer therapy What potential is there for LSD1 inhibitors to reach approval for AML Medicinal chemistry insights in the discovery of novel LSD1 inhibitors LSD1/KDM1A inhibitors in clinical trials: advances and prospects Polymyxins and quinazolines are LSD1/KDM1A inhibitors with unusual structural features Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties Natural protoberberine alkaloids, identified as potent selective LSD1 inhibitors, induce AML cell differentiation Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia The biological potential of flavones Flavones: an important scaffold for medicinal chemistry Baicalin, a natural LSD1 inhibitor Bioactivity-guided cut countercurrent chromatography for isolation of lysine-specific demethylase 1 inhibitors from Scutellaria baicalensis Georgi Flavone-based natural product agents as new lysine-specific demethylase 1 inhibitors exhibiting cytotoxicity against breast cancer cells in vitro Dual/multitargeted xanthone derivatives for Alzheimer's disease: where do we stand? Xanthones and cancer: from natural sources to mechanisms of action Xanthones as potential antioxidants Xanthones, a promising anti-inflammatory scaffold: structure, activity, and drug likeness analysis Bioactivity and pharmacological properties of α-mangostin from the mangosteen fruit: a review Alpha-mangostin from mangosteen (Garcinia mangostana Linn.) pericarp extract reduces high fat-diet induced hepatic steatosis in rats by regulating mitochondria function and apoptosis Bioactivity evaluation of natural product α-mangostin as a novel xanthone-based lysine-specific demethylase 1 inhibitor to against tumor metastasis Stilbene derivatives as new perspective in antifungal medicinal chemistry The use of stilbene scaffold in medicinal chemistry and multi-target drug design Aza-and azo-stilbenes: bio-isosteric analogs of resveratrol Synthetic approaches toward stilbenes and their related structures Cellular and molecular effects of resveratrol in health and disease Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan Natural Polyphenols inhibit lysine-specific demethylase-1 in vitro Histone demethylase LSD1 is required to induce skeletal muscle differentiation by regulating myogenic factors Discovery of resveratrol derivatives as novel LSD1 inhibitors: design, synthesis and their biological evaluation Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy Naturally occurring diarylheptanoids Characterization of diarylheptanoids: an emerging class of bioactive natural products Curcumin: the spicy modulator of breast carcinogenesis The essential medicinal chemistry of curcumin Chemopreventive and chemotherapeutic potential of curcumin in breast cancer Development of curcumin as an epigenetic agent Curcumin as an alternative epigenetic modulator: mechanism of action and potential effects Design, synthesis and biological evaluation of curcumin analogues as novel LSD1 inhibitors Is curcumin bioavailability a problem in humans: lessons from clinical trials The therapeutic potential of curcumin: a review of clinical trials Melatonin: an ancient molecule that makes oxygen metabolically tolerable Melatonin and its ubiquitous anticancer effects Potential of melatonin as adjuvant therapy of oral cancer in the era of epigenomics Melatonin as a treatment for gastrointestinal cancer: a review Melatonin induces histone hyperacetylation in the rat brain Epigenetic targets for melatonin: induction of histone H3 hyperacetylation and gene expression in C17.2 neural stem cells Melatonin induces apoptosis of colorectal cancer cells through HDAC4 nuclear import mediated by CaMKII inactivation Melatonin exerts anti-oral cancer effect via suppressing LSD1 in patient-derived tumor xenograft models Inhibition of lysine-specific demethylase 1 by the acyclic diterpenoid geranylgeranoic acid and its derivatives Extra virgin olive oil contains a phenolic inhibitor of the histone demethylase LSD1/KDM1A Histone demethylase LSD1 is a folate-binding protein Crystal structure of the histone lysine specific demethylase LSD1 complexed with tetrahydrofolate Targeting histone lysine demethylase LSD1/KDM1A as a new avenue for cancer therapy Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A) Synthesis, structure−activity relationship studies and biological characterization of new Design, synthesis and biological evaluation of [1,2,4] triazolo [1,5-a] pyrimidines as potent lysine specific demethylase 1 (LSD1/KDM1A) inhibitors Experience-based discovery (EBD) of aryl hydrazines as new scaffolds for the development of LSD1/KDM1A inhibitors Identification of osimertinib (AZD9291) as a lysine specific demethylase 1 inhibitor We are grateful for the financial support from the National Natural Science The authors have no conflicts of interest to declare.